Neogenomics Inc
NASDAQ:NEO
Neogenomics Inc
NASDAQ:NEO
Price:
15.3 USD
3.94%
Market Closed
Updated:
May 4, 2024
Neogenomics Inc
Cash from Financing Activities
|
Neogenomics Inc
Cash from Financing Activities Peer Comparison
Comparables:
TMO
DHR
MTD
A
IQV
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Neogenomics Inc
NASDAQ:NEO
|
Cash from Financing Activities
$4m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash from Financing Activities
-$3.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Danaher Corp
NYSE:DHR
|
Cash from Financing Activities
-$144m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
17%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash from Financing Activities
-$859.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-13%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cash from Financing Activities
-$1.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash from Financing Activities
-$382m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
See Also
What is Neogenomics Inc's Cash from Financing Activities?
Cash from Financing Activities
4m
USD
4m
USD
Based on the financial report for Mar 31, 2024, Neogenomics Inc's Cash from Financing Activities amounts to 4m USD.
What is Neogenomics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-47%
-47%
Over the last year, the Cash from Financing Activities growth was -44%. The average annual Cash from Financing Activities growth rates for Neogenomics Inc have been -83% over the past three years , -47% over the past five years .
You don't have any saved screeners yet
